Market Overview - The pharmaceutical commercial sector experienced a decline of 0.29% on September 10, with Dazhenglin leading the drop [1] - The Shanghai Composite Index closed at 3812.22, up 0.13%, while the Shenzhen Component Index closed at 12557.68, up 0.38% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with Seer Medical (603716) rising by 3.99% to a closing price of 28.70, and Dazhenglin (603233) falling by 2.37% to 17.30 [1][2] - Other notable gainers included Guofa Co. (600538) with a 1.65% increase and Dazhangzhang (002462) with a 1.22% increase [1] Trading Volume and Value - Seer Medical had a trading volume of 250,500 shares and a transaction value of 719 million yuan, while Dazhenglin had a trading volume of 77,200 shares and a transaction value of 134 million yuan [1][2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 11.87 million yuan from institutional investors and 50.86 million yuan from speculative funds, while retail investors contributed a net inflow of 62.74 million yuan [2] - Specific stocks like Seer Medical and Jiuzhoutong (600998) had significant net inflows from institutional investors, while others like Yifeng Pharmacy (603939) experienced net outflows from both institutional and speculative funds [3]

Core Points - The company, China National Pharmaceutical Group Corporation, is holding its third extraordinary general meeting of shareholders on September 15, 2025, to discuss the election of a new board member [1] - Zhang Ping has been nominated as a candidate for the board of directors, with her professional background detailed in the attached resume [1] - Zhang Ping has no shareholding in the company and does not have any relationships with other directors, senior management, or significant shareholders [2] Summary by Sections Meeting Details - The extraordinary general meeting will take place at 13:30 on September 15, 2025, at a specified location in Beijing [1] - Voting will be available through an internet platform during designated times [1] Election of Directors - The board of directors has proposed the election of Zhang Ping as a candidate for the eighth board of directors [1] - Zhang Ping's professional history includes various roles within China National Pharmaceutical Group, highlighting her experience in marketing management and risk management [1] Candidate Background - Zhang Ping was born in October 1978 and is a member of the Communist Party of China [1] - She has held positions in the company since 2011, with her most recent role being the director of business planning management in the risk and operations management department [1] - She does not hold any shares in the company and has no conflicts of interest with other stakeholders [2]

国药集团药业股份有限公司 1 / 5 SH.600511 国药股份 2025 年第三次临时股东会议程 现场会议时间：2025 年 9 月 15 日 13:30 交易系统平台网络投票时间： 2025 年第三次临时股东会会议资料 股票代码：600511 2025 年 9 月 15 日 2 / 5 SH.600511 一、审议关于选举董事的议案 报告人：罗丽春 总法律顾问、董事会秘书 2025 年 9 月 15 日 9:15-9:25，9:30-11:30，13:00-15:00； 互联网投票平台网络投票时间： 2025 年 9 月 15 日 9:15-15:00 现 场会 议 地点 ： 北 京市 东 城区 永 定门 西 滨河 路 8 号 院 7 楼中海地产广场西塔 8 层会议室 会议议题： 一、审议关于选举董事的议案 3 / 5 SH.600511 关于选举董事的议案 各位股东及股东代表： 公司于 8 月 29 日召开第八届董事会第二十九次会议，审议通过 了《关于提名董事候选人的议案》，提名张平女士（简历见附件）为 公司第八届董事会董事候选人。 以上议案提请股东会审议。 国药集团药业股份有限公司董事会 2025 ...

Core Viewpoint - The announcement details the change of the continuous supervision representative for the equity division reform of China National Pharmaceutical Group Corporation (国药股份) due to the retirement of the previous representative, Liu Xiangsheng, and the appointment of Lu Wenjun as his successor [1][2]. Group 1 - The company received a letter from the underwriting sponsor, Shenwan Hongyuan Securities, regarding the change of the continuous supervision representative for the equity division reform project [1]. - Liu Xiangsheng will no longer continue his duties due to retirement, and Lu Wenjun will take over the responsibilities [1]. - The board expresses gratitude for Liu Xiangsheng's contributions during his tenure [2]. Group 2 - Lu Wenjun has a master's degree and 16 years of experience in investment banking, having participated in various IPOs and financial advisory projects [4].

Core Viewpoint - The announcement details the change in the continuous supervision representative for the equity division reform of China National Pharmaceutical Group Corporation, with the new representative being Mr. Lu Wenjun, who has extensive experience in investment banking [1]. Group 1: Company Announcement - China National Pharmaceutical Group Corporation has received a letter from its sponsor, Shenwan Hongyuan Securities, regarding the change of the continuous supervision representative for its equity division reform [1]. - Mr. Liu Xiangsheng, the previous representative, is retiring and will be succeeded by Mr. Lu Wenjun, who will continue the supervisory duties [1]. - The board expresses gratitude for Mr. Liu's contributions during his tenure [1]. Group 2: New Representative Profile - Mr. Lu Wenjun holds a master's degree and has 16 years of experience in investment banking [1]. - He has led or participated in various IPO projects and private placements, including those for companies such as Furui Special Equipment, Dashengda, and Xianhui Technology [1]. - His experience also includes involvement in bond projects and asset restructuring for several companies, showcasing his extensive background in financial advisory [1].

Group 1 - The core point of the article is the announcement by China National Pharmaceutical Group Co., Ltd. (国药股份) regarding a change in the continuous supervision of its shareholding reform project due to the retirement of the previous supervisor [2] - Liu Xiangsheng, the former supervising representative for the shareholding reform, will be replaced by Shenwan Hongyuan's representative, Lu Wenjun, who will continue to fulfill the supervisory responsibilities [2]

证券代码：600511 证券简称：国药股份 公告编号：临 2025-032 国药集团药业股份有限公司 关于股权分置改革 持续督导保荐代表人变更的公告 2 附： 陆文军先生简历：保荐代表人，硕士研究生学历，具有16 年投行业务经历。曾主持或参与富瑞特装（300228）、大胜达 （603687）、先惠技术（688155）等首次公开发行并上市项目； 南宁糖业（000911）、美克家居（600337）、华铁应急（603300） 非公开发行股票项目；南宁糖业（000911）公司债；大胜达（603687） 可转债项目；济川药业（600566）资产重组项目；南宁糖业（000911） 资产收购；美克家居（600337）资产收购、誉衡集团收购信邦制 药（002390）等财务顾问项目。 公司董事会对刘祥生先生在持续督导工作期间所做出的贡 献表示衷心感谢。 特此公告。 1 国药集团药业股份有限公司董事会 2025 年 9 月 3 日 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性承担法律责任。 国药集团药业股份有限公司（以下简称"公司"或"国药股 份"）于近日 ...

Overview - The pharmaceutical manufacturing industry in China is experiencing robust demand due to an aging population, rising chronic disease incidence, and increased public health awareness [1][5] - By 2024, the number of large-scale pharmaceutical manufacturing enterprises in China is projected to reach 9,793, with total assets of 51,746.1 billion yuan, sales revenue of 25,298.5 billion yuan, and total profits of 3,420.7 billion yuan [1][5] - The normalization of centralized procurement is driving traditional pharmaceutical companies to shift from "scale expansion" to "lean survival," promoting the construction of a lean management system across the entire industry chain [1][5] Industry Classification - The pharmaceutical manufacturing industry can be divided into eight sub-sectors: chemical raw materials, chemical preparations, traditional Chinese medicine processing, traditional Chinese medicine production, veterinary medicine, biological products, sanitary materials, and pharmaceutical packaging [2] Development History - The industry has evolved from a weak foundation in the early years of the People's Republic of China, primarily relying on imported raw materials, to a rapidly expanding sector with significant improvements in manufacturing standards [3] - Key milestones include the establishment of the National Medical Products Administration in 1998 and the introduction of various policies to encourage innovation and improve drug quality [3][4] Development Background - The industry is supported by numerous policies aimed at correcting irregularities in the pharmaceutical procurement and medical service sectors, promoting digital traditional Chinese medicine, and enhancing the quality of traditional Chinese medicine [4][5] - The aging population is projected to reach 22,023 million by 2024, with a 1.60% year-on-year increase, leading to a growing demand for chronic disease medications [5][6] Industry Chain - The upstream of the pharmaceutical manufacturing industry includes suppliers of chemical raw materials, traditional Chinese medicine materials, and pharmaceutical packaging [6] - The midstream consists of pharmaceutical manufacturing companies, while the downstream includes medical institutions, health service organizations, pharmacies, and e-commerce platforms [6] Current Development Status - The pharmaceutical market's rigid demand is continuously expanding, with significant growth in the number of medical institutions and healthcare spending per capita [1][7] - By 2024, the number of healthcare institutions in China is expected to reach 1,092,000, with hospitals and grassroots medical institutions showing steady growth [7] Competitive Landscape - The pharmaceutical manufacturing industry is characterized by a diverse market with numerous participants, but recent reforms have led to increased concentration among leading companies [8] - Major players include China National Pharmaceutical Group, China Resources Pharmaceutical Group, and Shanghai Fosun Pharmaceutical, which have strong financial and R&D capabilities [8][9] Future Development Trends - The normalization of centralized procurement is expected to narrow profit margins for traditional generic drugs, prompting companies to increase investment in innovative drugs and high-barrier generics [10] - Pharmaceutical companies will focus on self-research and global collaboration, particularly in high-demand therapeutic areas like oncology and autoimmune diseases, while optimizing their supply chain management to reduce costs [10]

Group 1 - The company announced that its eighth board of directors held the 29th meeting, where it approved the proposal for nominating director candidates [2] - The company also approved the proposal to convene the third temporary shareholders' meeting in 2025 [2]

Group 1 - The board of directors of China National Pharmaceutical Group Corporation (referred to as "the company" or "China National Pharmaceutical") held its 29th meeting of the 8th board on August 2025, with all seven directors participating, including four independent directors [1][2] - The board unanimously approved the nomination of Ms. Zhang Ping as a candidate for the 8th board of directors, with a voting result of 7 in favor, 0 against, and 0 abstentions [1][2] - The proposal to convene the 2025 third extraordinary general meeting of shareholders was also approved with the same voting result [2] Group 2 - Ms. Zhang Ping, born in October 1978, has a bachelor's degree and has held various positions within China National Pharmaceutical Holdings Co., Ltd., including Deputy Director of Marketing Management and Senior Manager of Operations Management [2] - Ms. Zhang does not hold any shares in the company and has no related party relationships with other directors, senior management, or shareholders holding more than 5% of the shares [2]